Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Market volatility helps TP Icap to 'best ever' quarter

(Sharecast News) - TP Icap Group posted a surge in quarterly revenues Wednesday, as the City stalwart cashed in on recent market volatility. Total revenues jumped 10% in the three months to 31 March, to £629m, the broker's best-ever quarter and ahead of most analyst forecasts.

The firm said it had benefited from a period of "heightened market volatility, which was driven by the uncertainty of US trade policies".

Global broking revenues rose 14%, with strong trading in all asset classes, while its Liquidnet arm saw revenues strengthen 16%.

Energy and commodities revenues, however, were largely unchanged, hit by what TP Icap called a "competitive hiring market" for brokers.

Looking to the rest of the year, it said: "The board remains comfortable with the current market expectations for 2025 adjusted earnings before interest and tax, following a strong first quarter performance and despite the recent weakening of the US dollar."

Around 60% of group revenues and 40% of costs are dollar-denominated.

However, TP Icap also confirmed it had opted to temporarily shelve plans to proceed with a potential minority listing of data and analytics arm Parameta Solutions.

It announced in March that a potential Wall Street debut could happen as soon as the second quarter.

But on Wednesday the firm acknowledged that "following the recent market turbulence, the board will now keep under review the appropriate timing for any potential minority listing".

As at 1215 BST, shares in TP Icap were down 2% at 261.62p.

Vivek Raja, analyst at Shore Capital, said: "Though the statement makes to no reference to trading since the end of the first quarter, we suspect that the second quarter will have started well given tariff histrionics in early April.

"TP Icap's share price has been broadly rangebound over the last six months, having recent recovered ground since the market sell off in early April.

"We think the valuation is still undemanding in view of cash generation and case return prospects. If a potential delay in the timing of Parameta's listing results in share price weakness, we would see this as an opportunity."

Shore Cap has a 'buy' rating on the FTSE 250 stock.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.